Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Cork

Showing results (161-170 of 224) with videos related to

Pageof 23
Sort By:
Dermatology and Therapy|August 24, 2021
Dupilumab Demonstrates Rapid and Consistent Improvement in Extent and Signs of Atopic Dermatitis Across All Anatomical Regions in Pediatric Patients 6 Years of Age and OlderEric L Simpson, Amy S Paller, Elaine C Siegfried, et al.
European Journal of Immunogenetics : Official Journal of the British Society for Histocompatibility and Immunogenetics|February 14, 2002
Genetic analysis of the interleukin-1 receptor antagonist and its homologue IL-1L1 in alopecia areata: strong severity association and possible gene interactionR Tazi-Ahnini, A Cox, A J G McDonagh, et al.
American Journal of Clinical Dermatology|May 22, 2023
Efficacy and Safety of Abrocitinib in Patients with Severe and/or Difficult-to-Treat Atopic Dermatitis: A Post Hoc Analysis of the Randomized Phase 3 JADE COMPARE TrialEric L Simpson, Jonathan I Silverberg, Jacob P Thyssen, et al.
Plos One|March 26, 2015
Stability of the octameric structure affects plasminogen-binding capacity of streptococcal enolaseAmanda J Cork, Daniel J Ericsson, Ruby H P Law, et al.
Mbio|May 2, 2019
An Experimental Group A <i>Streptococcus</i> Vaccine That Reduces Pharyngitis and Tonsillitis in a Nonhuman Primate ModelTania Rivera-Hernandez, Diane G Carnathan, Scott Jones, et al.
Journal of the American Academy of Dermatology|June 1, 1996
Cyclosporine in severe childhood atopic dermatitis: a multicenter studyJ Berth-Jones, A Y Finlay, I Zaki, et al.
JAMA Dermatology|February 1, 2023
Efficacy and Safety of Dupilumab in Patients With Erythrodermic Atopic Dermatitis: A Post Hoc Analysis of 6 Randomized Clinical TrialsAmy S Paller, Jonathan I Silverberg, Michael J Cork, et al.
American Journal of Clinical Dermatology|March 28, 2026
Safety and Efficacy of Treatment with Dupilumab for up to 2 Years in Infants and Young Children with Atopic DermatitisAmy S Paller, Eric L Simpson, Elaine C Siegfried, et al.
The British Journal of Dermatology|December 2, 2017
Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ)M de Bruin-Weller, D Thaçi, C H Smith, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|December 2, 2021
Randomized controlled pilot trial with ion-exchange water softeners to prevent eczema (SOFTER trial)Z K Jabbar-Lopez, B Ezzamouri, A Briley, et al.
Pageof 23

Showing results (161-170 of 224) with videos related to

Sort By:
Pageof 23
Dermatology and Therapy|August 24, 2021
Dupilumab Demonstrates Rapid and Consistent Improvement in Extent and Signs of Atopic Dermatitis Across All Anatomical Regions in Pediatric Patients 6 Years of Age and OlderEric L Simpson, Amy S Paller, Elaine C Siegfried, et al.
European Journal of Immunogenetics : Official Journal of the British Society for Histocompatibility and Immunogenetics|February 14, 2002
Genetic analysis of the interleukin-1 receptor antagonist and its homologue IL-1L1 in alopecia areata: strong severity association and possible gene interactionR Tazi-Ahnini, A Cox, A J G McDonagh, et al.
American Journal of Clinical Dermatology|May 22, 2023
Efficacy and Safety of Abrocitinib in Patients with Severe and/or Difficult-to-Treat Atopic Dermatitis: A Post Hoc Analysis of the Randomized Phase 3 JADE COMPARE TrialEric L Simpson, Jonathan I Silverberg, Jacob P Thyssen, et al.
Plos One|March 26, 2015
Stability of the octameric structure affects plasminogen-binding capacity of streptococcal enolaseAmanda J Cork, Daniel J Ericsson, Ruby H P Law, et al.
Mbio|May 2, 2019
An Experimental Group A <i>Streptococcus</i> Vaccine That Reduces Pharyngitis and Tonsillitis in a Nonhuman Primate ModelTania Rivera-Hernandez, Diane G Carnathan, Scott Jones, et al.
Journal of the American Academy of Dermatology|June 1, 1996
Cyclosporine in severe childhood atopic dermatitis: a multicenter studyJ Berth-Jones, A Y Finlay, I Zaki, et al.
JAMA Dermatology|February 1, 2023
Efficacy and Safety of Dupilumab in Patients With Erythrodermic Atopic Dermatitis: A Post Hoc Analysis of 6 Randomized Clinical TrialsAmy S Paller, Jonathan I Silverberg, Michael J Cork, et al.
American Journal of Clinical Dermatology|March 28, 2026
Safety and Efficacy of Treatment with Dupilumab for up to 2 Years in Infants and Young Children with Atopic DermatitisAmy S Paller, Eric L Simpson, Elaine C Siegfried, et al.
The British Journal of Dermatology|December 2, 2017
Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ)M de Bruin-Weller, D Thaçi, C H Smith, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|December 2, 2021
Randomized controlled pilot trial with ion-exchange water softeners to prevent eczema (SOFTER trial)Z K Jabbar-Lopez, B Ezzamouri, A Briley, et al.
Pageof 23